There is a seismic shift occurring in how the world’s governments and payers value.

Innovative medicines and pricing dynamics. The rules of engagement for drug price negotiations have been fundamentally rewritten—not just in Washington, D.C., but in every major market across the globe.

In this keynote, we pull back the curtain on the “Payer Access Diaries.” These are the unfiltered, behind-the-scenes accounts of global payer negotiations from the last 18 months. These case studies come directly from the source: anonymized perspectives from the payer network, narrating the specific
strategies and renewed fervor they are bringing to the table when it comes to new drug launches, indication & lifecycle management and negotiation strategies that effect net price protection.

Keynote Themes

• The CMS Watershed: A deep dive into the US drug price negotiation landscape, how CMS is negotiating and its ripple effects on global innovation
• The Rare Disease Bubble: Analyzing the “Burst Phenomena” and why the industry’s safest haven is becoming its most volatile battleground.
• Payer Negotiation Revelations: Examining the specific negotiation strategies deployed in the context of MFN and how “value” is being redefined in real-time.

“These payer accounts won’t just inform your strategy; they will change your perspective on the future of the industry & will stay with you long after the conference ends.”